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The dental implications of bisphosphonates and bone disease
A Cheng,* A Mavrokokki,* G Carter,* B Stein,† NL Fazzalari,‡ DF Wilson,§ AN Goss*
Abstract
In 2002/2003 a number of patients presented to the
South Australian Oral and Maxillofacial Surgery
Unit with unusual non-healing extraction wounds of
the jaws. All were middle-aged to elderly, medically
compromised and on bisphosphonates for bone
pathology. Review of the literature showed similar
cases being reported in the North American oral and
maxillofacial surgery literature. This paper reviews
the role of bisphosphonates in the management of
bone disease. There were 2.3 million prescriptions
for bisphosphonates in Australia in 2003. This
group of drugs is very useful in controlling bone
pain and preventing pathologic fractures. However,
in a small number of patients on bisphosphonates,
intractable, painful, non-healing exposed bone
occurs following dental extractions or denture
irritation. Affected patients are usually, but not
always, over 55 years, medically compromised and
on the potent nitrogen containing bisphosphonates,
pamidronate (Aredia/Pamisol), alendronate
(Fosamax) and zolendronate (Zometa) for non-
osteoporotic bone disease. Currently, there is no
simple, effective treatment and the painful exposed
bone may persist for years. The main complications
are marked weight loss from difficulty in eating and
severe jaw and neck infections. Possible preventive
and therapeutic strategies are presented although at
this time there is no evidence of their effectiveness.
Dentists must ask about bisphosphonate usage for
bone disease when recording medical histories and
take appropriate actions to avoid the development
of this debilitating condition in their patients.
Key words: Bisphosphonates, bone disease, avascular
necrosis, jaws, dental treatment.
Abbreviations and acronyms: PEG = percutaneous
endoscopic gastrostomy.
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bisphosphonates have been found to be invaluable in
controlling pain and preventing fractures.
In Australia, there were 2.3 million bisphosphonate
prescriptions in 2003. This equals the number of
amoxycillin prescriptions in the same year.1 In 2004 this
had increased to 2.5 million bisphosphonate
prescriptions.1 Generally the side effects of
bisphosphonates are minimal. However, in 2003 there
were sporadic case reports in the North American oral
and maxillofacial surgery literature of patients with
necrosis of the jaws following dental treatment.2-5 These
patients were all receiving bisphosphonates, mainly
pamidronate and zoledronate for the management of
multiple myeloma, and bone metastases from breast
cancer.
In South Australia, the Oral and Maxillofacial
Surgery Unit of the Royal Adelaide Hospital managed
five similar patients who were suffering from
osteonecrosis of the maxilla and mandible in 2003.6-8
The patients’ ages ranged from 57 to 84 years and
comprised two females and three males. Three of the
patients suffered from Paget’s disease and two from
multiple myeloma. They were undergoing treatment
with either pamidronate or alendronate. Both
medications are nitrogen containing bisphosphonates
and have high affinity for bone tissue. From 2003 to
June 2005 a further 10 cases were diagnosed, bringing
our total experience to 15 patients.
The patients received a range of treatment from
conventional non-surgical intervention to aggressive
surgical re-section of the mandible and maxilla. Of the
original group of five, two patients experienced pain
relief after less than one year of treatment and three had
ongoing chronic pain symptoms involving their jaws.
This has recently been reported in the Australian
medical literature.8 We are also anecdotally aware of
similar cases elsewhere in Australia and are currently in
the process of documenting this.
The discovery of the possible association between the
bisphosphonates and osteonecrosis of the jaws
prompted both the United States Food and Drug
Administration and Novartis, the manufacturer of
bisphosphonates used in cancer chemotherapy, to issue
a warning to health care professionals in September
2004. The warning contained information about
bisphosphonates and the risk of osteonecrosis of the
jaw.9 These actions have been paralleled in Australia
with an adverse drug reaction report in the medical
literature10 and the publication by Novartis of
guidelines for health professionals11 and patients.12
Dental practitioners should be aware of the possible
association between dental extraction and
INTRODUCTION
Bisphosphonates are a group of medications that
have become increasingly and more widely used in the
management of certain bone diseases (Table 1). Some of
these conditions, such as osteoporosis, are very
common, particularly in our ageing population.
Metastatic bone disease as the end stage of breast or
prostate cancer is common. Some conditions such as
Paget’s disease or fibrous dysplasia are less common
but debilitating. In all of these conditions,
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bisphosphonates, as bisphosphonates have become a
standard medication in treating bone diseases. The
dental management plan for these patients needs to be
carefully formulated to minimize the risk of avascular
necrosis of the jaws and allow for the overall health
care of the patient to be maintained.
In this paper, we present a review of the
bisphosphonates; the medical uses of bisphosphonates;
osteonecrosis of the jaws; clinical case presentations;




Bisphosphonates were initially formulated by
scientists in the middle of the 19th century. They were
first used in the textile, fertilizer and oil industries for
the prevention of scaling in pipes because of their
ability to inhibit calcium carbonate precipitation.13
Bisphosphonates were shown to have biological effects
as they inhibit bone resorption. In high doses inhibition
of ectopic and normal calcification can occur due to the
physico-chemical inhibition of calcium phosphate
crystal formation.13,14
Chemistry
Bisphosphonates are synthetic compounds with a
chemical structure similar to that of inorganic
pyrophosphate, an endogenous regulator of bone
mineralization. While pyrophosphate is comprised of
two phosphate groups linked by phosphoanhydride
bonds (P-O-P structure), bisphosphonates are
comprised of two phosphonate groups linked by
phosphoether bonds (P-C-P structure). This structure
makes them more resistant to hydrolysis in acid
conditions or by pyrophosphatases.15,16 The chemical
structure of the basic bisphosphonate molecule renders
it easy to modify and, therefore, the biological,
therapeutic and toxicological characteristics of
different generations of bisphosphonates vary
dramatically.13,15
Types of bisphosphonates
Currently, there are two main types of
bisphosphonates: nitrogen containing and non-nitrogen
containing. Most of the bisphosphonates available
today are used for inhibition of bone resorption in the
treatment of bone diseases (Table 1).
Bone physiology
Bone is a dynamic tissue that constantly remodels.
The maintenance of healthy bone tissue relies on a
balance between bone resorption and mineralization of
bone matrix formation. The former is osteoclastic
activity, the latter osteoblastic activity. Generally
speaking, the older or non-functional bone is resorbed
by osteoclasts and new bone formed by osteoblasts.
The balance between these activities determines
whether there is net bone formation or resorption 
(Fig 1).
Mechanisms of action
The mechanisms of action of bisphosphonates in
bone metabolism are complex. Bisphosphonates act
almost exclusively on bone when administered at
physiological doses because of specific affinity to bone,
where they deposit both in newly formed bone and in
proximity to the osteoclasts. The half-life of
bisphosphonates in the circulation is quite short,
ranging from thirty minutes to two hours.14 However,
once incorporated into bone tissue, they can persist for
up to 10 years, depending on the skeletal turnover
time.14,15 This prolonged skeletal retention can explain
why single or short courses of intravenous injections
can be effective for a long time in the management of
Paget’s disease.14
Bisphosphonates act on bone through several
mechanisms simultaneously. For example, they can
both decrease osteoclast activity and decrease
osteoclast numbers. The first is exemplified by
internalization by osteoclasts, causing disruption of
osteoclast-mediated bone resorption,2 the second by
inhibiting osteoclast recruitment and accelerating
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Table 1. Dentists should mandatorily check the
following points in all medical histories
Do you have any bone diseases?
– Osteoporosis
– Paget’s disease
– Cancer with spread to the bones 
– (breast, prostate, liver, lung and kidney)
– Multiple myeloma
– Other bone conditions
Are you taking any bisphosphonate medications?




Pamidronate (Aredia, Pamisol) Tiludronate
Zoledronate (Zometa)
If positive to any of these questions, do not proceed to extraction or
surgery without advice.
Fig 1. Normal bone physiology - Bisphosphonates affect
angiogenesis, osteoclastic activity, osteoblastic activity and are
incorporated in the bone matrix.
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programmed cell death (apoptosis) of osteoclasts, thus
reducing osteoclast numbers. Both mechanisms lead to
reduction of bone resorption and to a decrease in bone
turnover.13
The two families of bisphosphonates have different
pathways via which they may act. Nitrogen containing
bisphosphonates generally act through the mevalonate
pathway but non-nitrogen containing bisphosphonates,
such as etidronate, tiludronate and clodronate, are
incorporated into the phosphate chain of ATP-
containing compounds so that they become non-
hydrolysable. The new P-C-P containing ATP
analogues inhibit cell function and lead to cell death by
apoptosis.13,16
Of relevance to bone healing, Kapitola et al. reported
bisphosphonates depress bone blood flow in rats and
significantly decrease circulating levels of vascular
endothelial growth factor which is important in the
angiogenesis process.2,17,18
In summary, bisphosphonates are non-metabolized
analogues of pyrophosphate that are capable of
localizing to bone and inhibiting osteoclastic
function.19,20 Bisphosphonates bind avidly to exposed
bone mineral around resorbing osteoclasts, resulting in
very high levels of bisphosphonates in the resorption
lacunae. Because bone-incorporated bisphosphonates
are not metabolized, these high concentrations are
maintained within bone for long periods of time.
Clinical uses
One of the early clinical uses of bisphosphonates was
as bone scan imaging agents. They remain very useful
for detecting bone metastases and other bone lesions.
Bisphosphonates are now used as the treatment of
choice for inhibition of bone resorption in diseases
where no effective treatment previously existed.
Paget’s disease is a common, non-metabolic disease
of bone of undetermined aetiology. It usually affects the
middle-aged and elderly. It is initially characterized by
excessive bone destruction but this is followed by
unorganized bone repair and remodelling. The
condition is mostly asymptomatic but some patients
may present with bone pain and pathological fractures,
and the bisphosphonates control this.15
Bisphosphonates also play a role in the management of
osteoporosis, a common disorder characterized by
abnormal rarefaction of bone. Osteoporosis occurs
most frequently in post-menopausal women but can
also affect males. The condition is also common in
immobilized individuals and patients who are on long-
term steroid therapy. The principal effect is to
predispose individuals to pathological fracture with
consequent pain and disability.20
Hypercalcemia is usually a result of excessive bone
resorption and release of calcium into the circulation. It
is secondary to bony metastatic malignancy,
hyperparathyroidism, or a humoral effect of neoplasia.
Patients can present clinically with confusion, anorexia,
abdominal pain, muscular pain and weakness. If
untreated it may progress via dehydration to renal
failure and death. Bisphosphonates rapidly normalize
serum calcium levels in most patients, irrespective of
the underlying aetiology.
Bisphosphonates effectively reduce the complications
of the malignant osteolytic process. They reduce bone
pain, the incidence of hypercalcemia and pathologic
fracture, and the need for palliative radiotherapy.
Multiple myeloma is a primary malignant neoplasm of
the bone marrow. The tumor is composed of neoplastic
plasma cells which destroy the osseous tissue, especially
in flat bones such as the ribs, skull and pelvis. The use
of bisphosphonates significantly improves the
management of multiple myeloma.15 Overall,
bisphosphonates improve the quality of life of patients
suffering from abnormal bone resorption by reducing
the number of pathological fractures and bone pain.
Osteonecrosis of the jaws
Since the initial reports2,4-8 there has been
considerable interest in this new variant of osteo-
necrosis associated with bisphosphonates. The
similarity of bisphosphonate-related osteonecrosis of
the jaws to the historical entity of phosphorous necrosis
or ‘phossy jaw’ has been noted.21 In the mid-19th
century match making workers suffered severe jaw pain
which was initially diagnosed as toothache. Extractions
made the condition worse, with a non-healing socket,
sequestration, pain, offensive smell, soft tissue
infections and deformity.22 The condition persisted for
years and there was a mortality rate of 20 per cent from
spreading infection. It was eventually determined that
this condition was associated with industrial contact
with white phosphorous. Cases of ‘phossy jaw’
continued into the 20th century, mainly in workers in
the munitions industry. ‘Phossy jaw’ was eventually
eradicated by changes in industrial hygiene.
In the early 20th century similar cases of jaw necrosis
were seen in workers applying radium to watch and
instrument dials to make them luminescent.23 This too
was eradicated by changes in industrial hygiene.
Currently, osteonecrosis of the jaws is secondary to
radiotherapy for head and neck cancer. Initially
osteoradionecrosis was thought to be bacterial. It is
now thought to be secondary to avascularity of the
bone. Treatment protocols involve hyperbaric oxygen
and surgical re-section.24
Initially, the first diagnosed cases of bisphosphonate
necrosis were treated with similar techniques as for
osteoradionecrosis.8,24 These techniques failed to be
effective as bisphosphonates involve the whole jaw
bone and indeed all of the skeleton whereas
radiotherapy affects only the localized field. With
osteoradionecrosis there is a reservoir of unaffected
bone in the area which can respond.
The histological appearance of 20 samples of
bisphosphonate affected bone has been reported.21
Generally, the bone showed reduced osteoclastic and
reversal line activity. The vascularity of the connective
tissue was intact but congested with red blood cells.
Bacterial colonies surrounded by inflammatory cells
were prominent. These findings are similar to those
noted in our cases (Figs 2a and 2b).
The maxillary bone of two cases were analysed by
back-scattered electron imaging to measure the degree
of bone tissue-level mineralization and the number of
osteocyte lacunae in the mineralized bone tissue. One
78-year-old female (Case 4) with Paget’s disease,
treated with pamidronate 90mg IV monthly for 18
months, showed high bone tissue-level mineralization,
greater than the 95th percentile of adult proximal
femoral bone. The mineralization was associated with a
reduced number of osteocyte lacunae in the bone
indicative of necrosis in some regions of the biopsy.
One 75-year-old female (Case 7) with multiple
myeloma, treated with pamidronate 90mg IV monthly
for four years, was slightly less mineralized than the
case above but still highly mineralized and associated
with active resorption. The active resorption perhaps
contributed to the slightly lower level of mineralization
and an apparent normal number of osteocyte lacunae
in the presence of osteomyelitis. In both cases, the bone
samples were obtained whilst the patients were
surgically treated for severe soft tissue infections.
Further quantitative bone analysis and comparison
with control jaw bone samples are necessary to
understand the significance of these observations.
Current aetiologic possibilities for bisphosphonate
necrosis are centred upon the effects of
bisphosphonates on the inhibition of angiogenesis18 and
osteoclastic action.25 It is also not known whether the
jaw bones metabolize bisphosphonates in the same way
as the long bones.
It is uncertain if the the term avascular necrosis is
correct, although it has been widely used. Does the
bone die because it loses its vascularity or does it die
then lose its vascularity? Similarly, bisphosphonate
osteomyelitis implies an inflammatory pathogenesis.
For these reasons the term ‘bisphosphonate
osteochemonecrosis of the jaw’ has been suggested.21
However, this is a very long name and ‘bis-phossy jaw’
has a simple and historical attractiveness.21
Clinical cases
The first five cases treated by the South Australian
Oral and Maxillofacial Surgery Unit have been
published previously.8 All patients remain alive and
under regular review. The previously presented cases
are updated in Table 2.
Subsequent cases treated by the Unit are presented in
Table 3 and all patients are summarized in Table 4. The
most striking features were that these patients were
generally older, medically compromised patients with
ongoing debilitating jaw pain. Weight loss was a
problem and two patients required percutaneous
endoscopic gastrostomy (PEG) feeding. Once
established, the neck and jaw infections could not be
eliminated as it was not possible to remove the cause,
the dead jaw.26 Hence they recurred and could only be
controlled by intermittent antibiotics. One patient
required a tracheostomy to control her airway. Of the
three who resolved in less than one year, all were on
alendronate. Two of the three cases of osteoporosis
were in the resolved group. Two severe longstanding
patients have resolved after 2+ years. Nine of 15 are
ongoing.
Dental implications
The discovery of the possible association between
bisphosphonate therapy and avascular necrosis of the
jaws is relatively recent and our current understanding
of the process is limited. From the recent literature from
Australian,8 North American,2,4,5,11,19 Singaporean27 and
Canadian28 sources, bisphosphonates appear to be a
direct factor in a multifactorial aetiology leading to
avascular necrosis in the jaws. It has been suggested
that the bisphosphonates produce ischaemic changes in
the maxilla and mandible. The fact that these
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Fig 2a. (Case 7) Low power photomicrograph showing irregular but
largely vital bone trabeculae composed of ‘old’ and ‘new’ bone
matrix and focally and chronically inflamed stromal connective
tissue. The microscopic picture in this area is one of low grade non-
suppurative chronic osteomyelitis. Original magnification x 40.
H&E.
Fig 2b. (Case 7) Photomicrograph showing non-vital bone with
empty osteocyte lacunae and prominent evidence of osteoclastic
resorption. The bone shows evidence of bacterial colonization (B).
Original magnification x 100. H&E.
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complications were not recognized during the trial
phase of these drugs suggests that the effect of the drugs
when they become incorporated in the bones might be
cumulative in nature. A recent study of multiple
myeloma patients treated with zoledronate acid showed
a progressively increasing incidence of osteonecrosis of
the jaws to 10 per cent by 36 months. With
pamidronate the incidence was lower to four per cent
by 36 months.29
The unique environment of the oral cavity could
explain why the maxilla and mandible are solely
involved. It can be hypothesized that patients who have
received long-term bisphosphonate therapy may have a
compromised blood supply to their maxilla and
mandible. When dental extractions are performed on
this group of patients, the open bony wound with a
compromised healing ability cannot cope with the
presence of oral microflora.28 The extraction wound
then becomes infected and progresses into osteomyelitis
due to the poor healing ability of the tissues. It then
develops into osteonecrosis.28 It should be noted that all
other bones in the skeleton are well enclosed in the soft
tissue and thus protected from a resident microflora.
Clinical management
Medical practitioners treating bone disease with
bisphosphonates need to be aware there is a small risk
their patient may develop the painful, debilitating and
difficult to treat condition of ‘bis-phossy jaw’. The
indication and bisphosphonate regimen used needs to
be carefully considered. The need for the patient to be
dentally fit and prepared to maintain this state for life
should be part of the informed consent for treatment.
Given the clinical benefit22,24 there is no need to
withdraw bisphosphonates from the market. However,
legal aspects have already been raised in the US.30
As the Australian population ages, dental management
of dentate patients undergoing bisphosphonate therapy
will become a common issue. It can be divided into
preventive and therapeutic management.
Preventive recommendations
A comprehensive recent medical history is essential
before commencing any dental treatment. Identifying
the risk factors in the medical history is mandatory and
will help the patient’s overall well-being and safety.
Patients taking potent bisphosphonates for more than
one year, particularly for bone conditions other than
osteoporosis, and those on concomitant steroids appear
to be at highest risk of developing ‘bis-phossy jaw’.
Other factors that appear to further increase the risks
include: residual multiple myeloma or another
malignancy; hypoproteinemia; renal impairment from
disease or drugs; and/or chemotherapy.
The treatment plan for a patient who has been on
bisphosphonate therapy should involve restorative
Table 2. Clinical details of five patients with avascular necrosis of the jaw in South Australia, 20038
Case Age, Presentation Precipitant Bisphosphonate Other medications Treatment Outcome 2005Sex (indication) 2003 status
1 57, M Painful Tooth Pamidronate Dexamethasone, Hyperbaric Persistent No pain
(Fig 3) exposed bone extraction (90mg IV methotrexate, oxygen, necrosis of Feels well
in maxilla and monthly for warfarin, folic acid, Le fort I level midface and Large
mandible 6 years) ranitidine, metformin, maxillectomy, mandible. defect
(Multiple myeloma) hydroxychloroquine, bisphosphonate PEG feed.
verapamil, sertraline, continued
morphine
2 64, M Ulcer R hard Tooth Pamidronate Prednisolone, Sequestrectomy, Resolution Resolution
palate with extraction (90mg IV cyclosporine, local
bone monthly for itraconazole, debridement,
sequestrum 2 years) sulfamethoxazole- bisphosphonate
(Multiple myeloma) trimethoprim, continued
ranitidine, penicillin
3 73, M Pain, swelling Tooth Alendronate Amlodipine, tramadol, Local Resolution Resolution
anterior extractions (40mg orally perindopril debridement,
maxillary daily for 5 years) sequestrectomies,




4 78, F Painful Denture Pamidronate None. Initially Hyperbaric Persistent 2 major
exposed bone pressure (90mg IV monthly reported8 as no oxygen, local areas of episodes of
in maxilla for 18 months) other medications but debridement, exposed infection.
(Paget’s disease) has significant non- denture reline, bone Weight loss.
medication problems bisphosphonate PEG
• Pharyngeal SCC ceased
Surgery and RT
• Pneumonia
5 84, F Non-healing Tooth Pamidronate Diltiazem, simvastatin, Wide intra-oral Persistent Persistent
extraction site extraction (60mg IV monthly ferrous sulphate, re-section with fistula fistula,
in left maxillary for 6 months) aspirin, bendrofluazide primary flap intermittent
alveolus (Paget’s disease) closure, antibiotics
bisphosphonate
ceased
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Table 3. Clinical details of patients seen in South Australia 2004-2005
Case Age, Presentation Precipitant Bisphosphonate Other medications Treatment OutcomeSex (indication)
6 72, M Non healing Tooth Alendronate Nil Mouth rinses Resolved
extraction extraction 40mg weekly
sockets for 3 years
maxilla (Osteoporosis)
7 75, F Submandibular Tooth Pamidronate Thalidomide 100mg daily Local debridement, Ongoing,
(Fig 1) swelling and extraction 90mg IV severe soft tissue (Severe
exposed left monthly for infections x 3. infections)
mandible 4 years (Multiple Tracheotomy
myeloma)
8 69, M Exposed right Tooth Alendronate Diabex, noten, lipex, kapanol, Local Ongoing
and left extraction 40mg weekly calcitonin, tryptanol debridement, Low grade
mandible for 6 months mouth rinses infection
(Paget’s disease)
9 82, F Exposed Tooth Pamidronate Thyroxine Declined treatment, Ongoing
mandibular extraction (90mg IV every NSAIDS antibiotics for – Draining
surface with 3 months for fistula – fistula
pus drainage 5 years) – Lost 32kg
and cutaneous Alendronate – Declined
fistula (20mg orally daily, – for 2+
1 year) – years
(Paget’s disease)
10 72, F Submental Tooth Pamidronate Thalidomide 100mg daily Mouth rinses Ongoing
(Fig 4) abscess, extraction 90mg IV for – 1 severe
exposed right 3 years – infection




11 39, M Oroantral Tooth Alendronate Nil Mouth rinses Resolved
fistula with extraction 40mg weekly for
pus discharge 1 year
(Osteoporosis)
12 78, M Painful Tooth Pamidronate Rani-2, iscover, pexsig, Local debridement Ongoing
maxilla in extraction (Metastatic cardizem, digoxin, review, large
anterior and prostate cancer) tofranil maxillary
posterior region bony defect
13 58, M Painful non Tooth Pamidronate MS-Contin, baclofen, zoloft Local debridement Deceased of
healing right extraction (for 8 years) Primary closure acute bone
mandible (Multiple myeloma) after 18 months bone marrow
transplant
rejection
14 58, F Painful right Deep bony Alendronate Bactrim, Alendronate Non surgical Ongoing
(Fig 4) mandible impacted 40mg weekly started Neurontin, endep management review.
wisdom tooth after tooth removal Patient has
removal (Osteoporosis) lost 10%
body weight
in 10 months
15 74, M Painful left Tooth Zoledronic acid 3 Anandron, calcitriol, digoxin, Non surgical Ongoing
mandible extraction years (Metastatic dexamethasone, warfarin, management. treatment
prostate cancer) frusemide, omeprazole Endodontics
Table 4. Summary of all Adelaide cases to date
Age OtherNo. (median Sex Involved jaw Precipitant Bone disease Bisphosphonate Treatment medications Complications* Outcomerange)
15 69 9M Maxilla 8 Tooth Multiple myeloma 5 Pamidronate 8 HBO and Yes 13 Large defect 2 Ongoing 9
(34-84) 6F Mandible 6 extraction 14 Paget’s disease 5 Alendronate 5 re-section 1 Nil 2 Persistent Resolved
Both 1 Denture Bone cancer 2 Pamidronate Re-section 1 fistula 1 <1 yr 3
irritation 1 Osteoporosis 3 and HBO and Serious Resolved
Alendronate 1 curettage 1 infection 4 <2 yr 2
Zoledronate 1 Curettage 6 Feeding Died other
Non-surgical difficulty 4 cause 1
only 6 No major
complications 8
*some multiple
S10 Australian Dental Journal Medications Supplement 2005;50:4.
dentistry, limited non-surgical periodontics and
endodontics to control dental decay, periodontal
disease and periapical inflammation. Patients who have
dentures should have well maintained soft liners to
minimize trauma to the oral mucosa or leave their
dentures out. Failing soft liners would be more
irritating than a hard but smooth denture. Extraction
and all types of surgery should be avoided. If an
extraction is mandatory, for example an infected
vertically split tooth, then the tooth should be extracted
with minimal bony damage or exposure. Although
there is no research to validate it, prophylactic
antibiotics31 and suturing the socket to close the wound
are advised. As a novel approach the authors have been
using orthodontic elastic bands to exfoliate teeth. This
results in a slow extraction over a few weeks which
allows the oral mucosa to migrate down the tooth as it
exfoliates so there is no open wound.32
There are conflicting reports regarding dental
implants. Experimental studies show a positive effect of
bisphosphonates on the bone around implants in
experimental animals33,34 and humans.35 Failure of
osteintegration in a patient who had successfully
integrated implants but then commenced on
bisphosphonate therapy has been reported.36 Current
advice is that placement of implants is best avoided if
the patient has serious bone disease and are on potent
doses. Osteoporotic patients on lower doses need a full
informed consent before proceeding. Patients on
bisphosphonate therapy with existing implants should
be regularly clinically and radiographically monitored.
Increased bone density around the implant, similar to
Fig 3a. Case 1. Clinical appearance 2003, following right maxillary
extractions. Right maxillary necrotic area (long arrow) left
sequestrium (short arrow).
Fig 3b. CT maxilla and mandible 2003, post extraction and prior to
re-section. Lines show level of maxillectomy and subsequent left
mandibulectomy.
Fig 3c. Clinical appearance 2005. Tissue healthy, no pain. No
obturator but eats soft food via mouth. Had a percutaneous
endoscopic gastrostomy (PEG) feeding for 18 months.
Fig 4a. Case 10. OPG radiograph 2003, just prior to extraction of
tooth 46. Socket did not heal but patient did not represent for
treatment. Arrow points to dense interseptal bone.
that shown around the socket in Fig 4c, may occur. If
bone pain or loss of integrity occurs the superstructure
should be removed and the implant left submerged.
Bone surgery must be avoided as the bone is
exceedingly dense and avascular necrosis may occur.
Full dental assessment and treatment planning
should occur prior to the patient commencing
bisphosphonate therapy (Table 5). If the
bisphosphonate therapy can be delayed without the
risk of other skeletal related complications, teeth with a
poor prognosis should be extracted and all surgical
procedures completed before the commencement of the
bisphosphonate therapy. The decision to withhold the
bisphosphonate therapy should be made by the treating
physician in consultation with an oral and
maxillofacial surgeon and dentist. Once
bisphosphonate therapy is commenced, regular dental
monitoring of oral health and a preventive approach
should be adopted. Patients should be educated
regarding good oral hygiene practice and report any
symptoms. Treating medical specialists, oncologists and
endocrinologists prescribing these drugs should
perform a brief oral exam during follow up
appointments and refer as appropriate.11
Therapeutic recommendations
The first step is to establish the diagnosis if a patient
on bisphosphonate therapy presents with a non-healing
oral wound. This requires an accurate medical and
dental history. Patients with diabetes, radiotherapy in
the head and neck region and immunocompromised
patients can have delayed wound healing. Once the
diagnosis of ‘bis-phossy jaw’ is made the treating
medical practitioner, oral and maxillofacial surgeon
and dentist need to confer to establish a management
plan. At present there is no simple single effective
treatment for ‘bis-phossy jaw’2-5,8,11 The first approach
should be non-surgical with the use of antiseptic mouth
rinses and antibiotics to prevent or treat secondary
infection. Removable appliances lined with a
periodontal pack that passively cover the bony defect
can be inserted to protect the site from further trauma
and may aid mucosal covering of the exposed bone.8,11
This is a slow process.
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Fig 4b. OPG 2005. Dense bone at the extraction site with two
dense spicules which look like tooth roots. (Arrow) These are a
thickening of the periodontal lamina and are present on the 2003
OPG (Fig 4a).
Fig 4c. Intra-oral view 2005. Exposed bone right alveolus. (Arrow)
Remaining teeth poor. Teeth with necrotic and infected pulps with
apical periodontitis have been treated endodontically.
Fig 4d. Presented in early 2005 with acute submandibular infection
and draining sinuses. Treated with drainage and antibiotics. Much
improved but draining fistulae continue.
Table 5. Preventive strategy for dental management of
patients about to start bisphosphonates
Proven indication for bisphosphonate therapy
As per Table 1.
Referral for dental assessment 
Establish dental fitness
– Eliminate caries (extractions, restorations)
– Establish healthy periodontium (scaling, extractions)
Commence bisphosphonate therapy
Regular monitoring of oral health
Clinical examination
Radiology
Dental – maintain oral health
Dental – avoid extractions, avoid dentures
S12 Australian Dental Journal Medications Supplement 2005;50:4.
If the exposed bone is painful or there is significant
secondary infection, localized surgical debridement
without primary reconstruction can be considered.
Minimal mucoperiosteal flap reflection to preserve the
blood supply to underlying bone should be used. The
problem is that the whole skeleton is involved. Re-
section to a normal bleeding bone margin cannot be
undertaken as for osteoradionecrosis. Bone grafting,
either as a free graft or by microvascular transfer,
involves affected bone. There is a risk that there could
be two problem areas, the donor graft site as well as the
recipient jaw site. Major re-section surgery should be
avoided if at all possible.2,4,5,8,11
In summary, for established cases it is recommended
that treatments begin with the recognition that
palliation and control of secondary infection are the
primary goals. Control of progression has been
obtained in most cases with long-term or intermittent
courses of a penicillin or second generation
cephalosporin, chlorhexidine mouthwash and periodic
minor debridement of soft-textured sequestrating bone
and wound irrigation (Table 6).
Future directions
There are many unknowns regarding the process of
bisphosphonate-related osteonecrosis of the jaws. The
precise pathophysiology is unknown. The incidence is
currently low, probably of the order of 0.1-1 per cent of
all patients on bisphosphonates. The incidence may
differ between different bone pathologies, different
bisphosphonates and different dosage regimens. The
most concerning question is whether this is a
cumulative problem. If bisphosphonates do continue to
accumulate within the bones until a threshold dose is
Table 6. Therapeutic management of established
avascular necrosis of the jaws
Ensure correct diagnosis
Cease bisphosphonate if possible
NB: Minimum 3 month duration before surgical intervention*
• Antibiotics if secondary infection (penicillin, cephalosporin or
clindamycin)
• Antiseptic mouthwash (e.g., Chlorhexidine gluconate)





Consider alternatives to Surgical re-section
bisphosphonate therapy without primary reconstruction
*It is probable that this time span is too short.
**Extreme caution is recommended at this point.
Fig 5a. Case 14. Resorbing horizontally impacted 48, uneventfully
removed in 2003. The patient was commenced on alendronate for
osteoporosis after the extraction.
Fig 5b. Bone pain right mandible. OPG 2005. 48 socket appears
normal, tooth 47 has a clinically normal pulp.
Fig 5c. CT scan mandible shows no bony infill of the socket
(Arrow) but dense mineralization around socket.
reached then the incidence of ‘bis-phossy jaw’ will
increase.29 The authors have established a number of
trials with the Bone and Joint Research Laboratory of
the Institute of Medical and Veterinary Science and
Multiple Myeloma and Paget’s disease clinics within the
Royal Adelaide Hospital, University of Adelaide Health
campus, in an attempt to answer these questions. All
the cases in Australia treated by oral and maxillofacial
surgeons are also being documented.
An interesting but unresolved question is to how best
to extract teeth in patients on bisphosphonates.
Currently, there is no evidence for the clinical
suggestions on extraction for patients on
bisphosphonates. The problem with such studies is that
as the risk is low a large study is required to obtain
statistical significance. If one variable – for example
simple forceps extraction versus elastic band
exfoliation – is better, then assuming a 1 per cent risk
of osteonecrosis to get to a p<.05 significance, a trial of
at least 2000 patients all on bisphosphonates and all
requiring extractions is needed!
There are important dental implications with
patients on bisphosphonates for bone disease but the
best practice answers are currently unknown.
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